Our data and the Recursion OS enable us to train intelligent machine learning models for AI drug discovery and development, which help us rapidly identify new targets and design highly …

6 days ago · A first-of-its-kind whole genome map from researchers at Recursion with partners Roche and Genentech offers a new approach to exploring novel targets and pathways for a …

Embark on a career journey with Recursion. Dive into opportunities, culture, and the impact you can make. Apply to work with us today!

Unlike traditional drug discovery, which begins with a specific target or hypothesis, we leverage the Recursion OS — our drug discovery and development platform for AI in pharma connects …

Leveraging the power of the Recursion OS, we are building an industry-leading pipeline of potential best-in-class and first-in-class therapeutic assets. We focus on indications with high …

6 days ago · Explore Recursion's latest blog posts on AI, automation, and molecular modeling in drug discovery. Stay informed with cutting-edge insights!

Ben Taylor comes to Recursion after over 4 years as the CFO of Exscientia. Ben has more than two decades of experience in healthcare investment banking and executive roles, including 15 …

The recursion mindset is the deep belief and commitment to industrializing drug discovery through automation, algorithms, and data to deliver on our mission. This is made manifest through our …

The release of Boltz-2 – a new machine learning model from MIT and Recursion that cannot only predict the 3D structure of ligand/protein complexes but predict their binding affinity with new …

At Recursion, Dr. Khan has combined bold vision with disciplined leadership to advance value and impact.